Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Gianfranco Ferraccioli

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

Lingua originale	English
pagine (da-a)	857-863
Numero di pagine	7
Rivista	Clinical and Experimental Rheumatology
Volume	31
Stato di pubblicazione	Pubblicato - 2013
Pubblicato esternamente	Sì

Keywords

rheumatoid arthritis
therapy

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{c962454d5a92482aa674c3de922126cb,

title = "Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database",

abstract = "To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.",

keywords = "rheumatoid arthritis, therapy, rheumatoid arthritis, therapy",

author = "Gianfranco Ferraccioli",

year = "2013",

language = "English",

volume = "31",

pages = "857--863",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology:Via S Maria 31, I 56126 Pisa Italy:011 39 050 40124, EMAIL: info@clinexprhematol.org, INTERNET: http://www.clinexprhematol.org, Fax: 011 39 050 502299",

}

TY - JOUR

T1 - Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

AU - Ferraccioli, Gianfranco

PY - 2013

Y1 - 2013

N2 - To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

AB - To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

KW - rheumatoid arthritis

KW - therapy

KW - rheumatoid arthritis

KW - therapy

UR - http://hdl.handle.net/10807/53998

M3 - Article

SN - 0392-856X

VL - 31

SP - 857

EP - 863

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

ER -

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Abstract

Keywords

Altri file e collegamenti

Fingerprint

Cita questo